Clinical trials: Secondary Hyperparathyroidism
Vitamin D Deficiency, Secondary Hyperparathyroidism
Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density
Because of its high sun exposure, Israel was traditionally supposed to be protected from vitamin D deficiency, and the country food products hardly contain vitamin D supplements.
- Conditions
- Vitamin D Deficiency, Secondary Hyperparathyroidism, Osteomalacia
- Trial name
- NCT01025128
- Testing
- 25 OH vitamin D
- Where
- Israel
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Clalit Health Services
Kidney Failure, Secondary Hyperparathyroidism
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
This is a pilot, prospective randomized controlled study with the primary objective to evaluate and compare medical treatment of severe SHPT, namely oral cinacalcet versus surgical treatment, that is, parathyroidectomy with…
- Conditions
- Kidney Failure, Secondary Hyperparathyroidism, Vascular Diseases
- Trial name
- PROCEED (NCT01447368)
- Testing
- Cinacalcet, Surgical total parathyroidectomy with forearm autografting
- Where
- Hong Kong
- Volunteers
- 67 people
- Sponsor
- The University of Hong Kong
Secondary Hyperparathyroidism
Phase 3 Study of KHK7580
This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis.
- Trial name
- NCT02549417
- Testing
- KHK7580
- Where
- Japan
- Volunteers
- 39 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Secondary Hyperparathyroidism
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National…
- Trial name
- NCT00135304
- Testing
- Sensipar®, Vitamin D
- Volunteers
- 170 people
- Sponsor
- Amgen
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease
Chronic Kidney Disease and Bone - Correlation Between 18F-PET-TT Imaging and Histomorphometry of Bone in CKD Patients
Chronic kidney disease (CKD) is an increasing public health problem and the number of patient with chronic kidney disease is increasing worldwide.
- Trial name
- CKD-Bone (NCT02967042)
- Testing
- 18F-PET-TT
- Where
- Finland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Secondary Hyperparathyroidism
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism
The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium…
- Trial name
- 1hydroxylase (NCT00754442)
- Testing
- Teriparatide
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Parathyroid Tumor, Primary Hyperparathyroidism
Parathyroid Tumor Clonal Status
To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will…
- Conditions
- Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
- Trial name
- NCT05997810
- Where
- United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Secondary Hyperparathyroidism
Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.
- Trial name
- NCT02143271
- Testing
- KHK7580
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary
Study on the Use of Cinacalcet in Phosphocalcic Context.
Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom parathyroidectomy is theoretically indicated but in whom it…
- Trial name
- CALCI-CINA (NCT04126954)
- Testing
- Serum PTH concentrations results
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hyperparathyroidism
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism
Based on the evidence that periostin is specifically involved in intra-cortical remodeling control, our working hypothesis is that assessment of its concentration in the serum would be helpful in identifying patients with severe…
- Trial name
- NCT02524041
- Testing
- HR-pQCT, blood specimen
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Nephrology
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters
- Trial name
- NCT00189501
- Testing
- Sensipar®
- Volunteers
- 1,000 people
- Sponsor
- Amgen
Renal Osteodystrophy
Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)
Bone and mineral disease is a key problem in patients with kidney disease. The available clinical parameters are non-specific, unproven for the assessment of the bone metabolism and do not reflect the complexity and diversity of…
- Trial name
- BoneX (NCT02556216)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannover Medical School
Hyperparathyroidism, Secondary
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males.
- Trial name
- NCT01134549
- Testing
- Etelcalcetide
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- KAI Pharmaceuticals
End-Stage Kidney Disease (ESKD), Cardiovascular Disease
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients
This prospective, single-center observational cohort study evaluates cardiovascular mortality risk in adults receiving maintenance hemodialysis.
- Conditions
- End-Stage Kidney Disease (ESKD), Cardiovascular Disease, Secondary Hyperparathyroidism (SHPT)
- Trial name
- NCT07769190
- Testing
- One-Year Serum Phosphate Target Achievement Rate, Parathyroidectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Huashan Hospital
Secondary Hyperparathyroidism
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to identify an appropriate starting dose of DP001 to be…
- Trial name
- NCT01653379
- Testing
- DP001
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Deltanoid Pharmaceuticals
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Vitamin D Deficiency
Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder
It is hypothesised that the efficacy and safety of Vitamin D2 soft capsule to treat the Chronic Kidney Disease Mineral and Bone Disease (CKD-MBD) are equal to 1,25(OH)2 Vitamin D3 (Rocaltrol) in the patients with CKD stage 3-5.
- Trial name
- NCT01633853
- Testing
- Vitamin D2, 1,25(OH)2 Vit D3
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Dongliang Zhang, MD
Hyperparathyroidism, Secondary
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis
This study evaluates the metabolic and clinical results of two well recognized and accepted surgical techniques in the management of severe hyperparathyroidism in patients under regular dialysis treatment.
- Trial name
- NCT02464072
- Testing
- Subtotal Parathyroidectomy, Total Parathyroidectomy + 45 autografts, Total Parathyroidectomy + 90 autografts
- Where
- Brazil
- Volunteers
- 133 people
- Sponsor
- University of Sao Paulo General Hospital